ROVI Laboratories has warned Friday that profitability in the exercise of 2024 has been lower than expected. In a relevant fact sent to the National Securities Market Commission (CNMV), which, “in the context of the preliminary closure of the 2024 exercise and in relation to the Ebitda de Rovi levels at the end of the aforementioned exercise 2024 provided by the consensus of the consensus of the Market, the company wants to anticipate that it provides that these Ebitda levels be lower, in a range of between 10 and 15%, at the levels by 2024 of the market consensus ”. The company’s shares, member of the Ibex 35, react in the stock market with falls of up to 19% in the first bars of the session.
According to the company, this review of the market consensus regarding the EBITDA is mainly motivated by a lower activity of the one provided for in the manufacturing business to third parties (CDM) during the fourth quarter of the 2024 closed year.
The company has specified that the complete results of exercise 2024 will be published on February 25, 2025. “At that time, society will provide information about the situation and about the analysis of its forecasts for exercise 2025,” he says.
In any case, the company has insisted that it maintains its forecasts for the current year 2025 already communicated.
Red Laboratories negotiated, in a transaction that could have been around 3,000 million euros, but, finally there was no agreement. This valuation was more than half of the stock market capitalization of the pharmaceutical company. The pharmaceutical company then said that, “given the strength, the good current performance and the prospects of this business”, the best way to maximize the value for shareholders currently went to continue executing the independent strategic plan of society, “protecting and developing The CDMO business under the current structure of the ROVI group, without the entry of external investors. ”
The company seeks to return to normal, once the stage marked by COVID-19, and recover the confidence of investors. The direction of Rovi plans to hold a Markets Day capital in the first part of 2025, which would focus on the long -term forecasts of the CDO division and other strategic bets around medicines such as Okedi. With that objective, last November, after canceling the operation with CVC, the company brought together more than twenty investors and analysts last week in Madrid to analyze the situation of this division and other activities.
The firm has lived a last year in a real Russian mountain in the stock market. In the first semester of 2024, in the heat of the sale of the CDMO business, the shares were fired, exceeding the level of 94 euros. However, in the second part of the year they suffered a strong decrease, until they lost the level of 58 euros at the beginning of 2025.
